Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alpha-Tocotrienol SCHEMBL29670863 | 0.85 | ALOX5 (0.82) | ALOX5 | |
| Alpha-Tocotrienol SCHEMBL29439361 | 0.85 | ALOX5 (0.82) | ALOX5 | |
| SCHEMBL29838335 | 0.85 | ALOX5 (0.82) | ALOX5 | |
| SCHEMBL23166910 | 0.85 | ALOX5 (0.82) | ALOX5 | |
| SCHEMBL29670840 | 0.85 | ALOX5 (0.82) | ALOX5 | |
| SCHEMBL23166911 | 0.85 | ALOX5 (0.82) | ALOX5 | |
| Alpha-Tocotrienol SCHEMBL31053049 | 0.85 | ALOX5 (0.82) | ALOX5 | |
| SCHEMBL23167044 | 0.85 | ALOX5 (0.82) | ALOX5 | |
| Alpha-Tocotrienol SCHEMBL2364445 | 0.85 | ALOX5 (0.82) | ALOX5 | |
| SCHEMBL29838380 | 0.85 | ALOX5 (0.82) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228454-A1 | RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASE IN TWO-PHASE SYSTEM | DSM IP ASSETS B.V. (NL) | 2024-07-11 | — | — | US | disclosed |
| US-20240228454-A1 | RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASE IN TWO-PHASE SYSTEM | DSM IP ASSETS B.V. (NL) | 2024-07-11 | — | — | US | disclosed |
| US-20240217941-A1 | RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASIC CATALYST | DSM IP ASSETS B.V. (NL) | 2024-07-04 | — | — | US | disclosed |
| US-20240217941-A1 | RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASIC CATALYST | DSM IP ASSETS B.V. (NL) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217941-A1 | RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASIC CATALYST | SQLE, VKORC1, TTPA | ALOX5 57/4885 |
| US-20240228454-A1 | RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASE IN TWO-PHASE SYSTEM | TTPA, SQLE, VKORC1 | ALOX5 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.